Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
Price : $35 *
At a glance
- Drugs Trichuris suis ova (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 14 Jan 2019 Status changed from active, no longer recruiting to completed.
- 07 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2018.
- 09 Oct 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2017 as reported by ClinicalTrials.gov record.